AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29794782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-coronary administration of tirofiban through aspiration catheter
Number of subjects: 89
Study 29794782 — intervention group
Group type: COMPARATOR
Intervention: Intra-coronary administration of tirofiban through guiding catheter
Number of subjects: 89
Study 27489202 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 3% gel
Number of subjects: 0
Study 27489202 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid 2% gel
Number of subjects: 0
Study 27489202 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 0
Study 25198263 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care management (n=42)
Number of subjects: 98
Study 25198263 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management (n=56)
Number of subjects: 98
Study 22608481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomographic neurofeedback (tNF) training using theta‐beta frequency and slow cortical potential (SCP) protocols
Number of subjects: 13
Study 22608481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomographic neurofeedback (tNF) training
Number of subjects: 13
Study 19834806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solutions (OSPS)
Number of subjects: 0
Study 19834806 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 0
Study 18030500 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangerine juice
Number of subjects: 10
Study 18030500 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 10
Study 16201292 — intervention group
Group type: EXPERIMENTAL
Intervention: Yaoliuan capsule
Number of subjects: 323
Study 16201292 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 323
Study 12898897 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alcohol consumption (5-37 years)
Number of subjects: 79
Study 12898897 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 persons who rarely drank alcohol)
Number of subjects: 79
Study 10569360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable suture anchors
Number of subjects: 40
Study 10569360 — intervention group
Group type: COMPARATOR
Intervention: Absorbable suture anchors
Number of subjects: 40
Study 8829933 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia (induction: 2-3 mg kg-1, maintenance: 6-10 mg kg-1 h-1)
Number of subjects: 60
Study 8829933 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone/halothane anaesthesia (induction: 4-6 mg kg-1, maintenance: halothane 0.8-1.5%)
Number of subjects: 60
Study 1984348 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (5 days)
Number of subjects: 20
Study 1984348 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise, 5 days)
Number of subjects: 20
Study 6527752 — intervention group
Group type: EXPERIMENTAL
Intervention: disulfiram (400 mg/day) for 6 days
Number of subjects: 8
Study 6527752 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 8
Study 6527752 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (80 mg/day) for 4 weeks
Number of subjects: 8
Study 30510410 — intervention group
Group type: EXPERIMENTAL
Intervention: Better living with COPD (intervention)
Number of subjects: 182
Study 30510410 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 182
Study 27730283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen (HFNC) combined with non-invasive ventilation (NIV)
Number of subjects: 49
Study 27730283 — intervention group
Group type: COMPARATOR
Intervention: NIV alone
Number of subjects: 49
Study 24617598 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic kinesio taping with tension
Number of subjects: 40
Study 24617598 — intervention group
Group type: COMPARATOR
Intervention: Sham kinesio taping without tension
Number of subjects: 40
Study 23078797 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal tailored letter with risk information and invitation to a taster session
Number of subjects: 4500
Study 23078797 — intervention group
Group type: COMPARATOR
Intervention: Standard generic letter advertising the local service
Number of subjects: 4500
Study 21134041 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (2 U/0.1 mL; 30 facial injections on half of the face, each 0.1 mL)
Number of subjects: 10
Study 21134041 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (30 facial injections on half of the face, each 0.1 mL)
Number of subjects: 10
Study 17641457 — intervention group
Group type: EXPERIMENTAL
Intervention: Red paper
Number of subjects: 0
Study 17641457 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue paper
Number of subjects: 0
Study 17641457 — intervention group
Group type: EXPERIMENTAL
Intervention: Red and Blue conditions
Number of subjects: 0
Study 15655139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of efalizumab weekly
Number of subjects: 556
Study 15655139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study 12174532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficacy condition
Number of subjects: 59
Study 12174532 — intervention group
Group type: COMPARATOR
Intervention: Low-efficacy condition
Number of subjects: 59
Study 9924155 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization procedures for patients with unstable angina with electrocardiographic changes
Number of subjects: 1010
Study 9924155 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization procedures for patients with rest chest pain
Number of subjects: 1010
Study 9924155 — intervention group
Group type: COMPARATOR
Intervention: Atherectomy
Number of subjects: 1010
Study 7751072 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate feeding (F)
Number of subjects: 32
Study 7751072 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-solid carbohydrate feeding (S)
Number of subjects: 32
Study 7751072 — intervention group
Group type: COMPARATOR
Intervention: Liquid placebo (P)
Number of subjects: 32
Study 2255352 — intervention group
Group type: EXPERIMENTAL
Intervention: External version
Number of subjects: 52
Study 2255352 — intervention group
Group type: EXPERIMENTAL
Intervention: External version with tocolysis
Number of subjects: 52
Study 2255352 — intervention group
Group type: COMPARATOR
Intervention: Initial attempts without tocolysis
Number of subjects: 52
Study 6969348 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole and lactobacilli preparation
Number of subjects: 68
Study 6969348 — intervention group
Group type: COMPARATOR
Intervention: Framycetin, colymycin, nystatin, and metronidazole
Number of subjects: 68
Study 30446826 — intervention group
Group type: EXPERIMENTAL
Intervention: Three PVB injections
Number of subjects: 200
Study 30446826 — intervention group
Group type: COMPARATOR
Intervention: Five PVB injections
Number of subjects: 200
Study 28476487 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopur® - Ferring
Number of subjects: 270
Study 28476487 — intervention group
Group type: COMPARATOR
Intervention: Meriofert® - IBSA Institut Biochimique SA
Number of subjects: 270
Study 28476487 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopur® - Ferring and Meriofert® - IBSA Institut Biochimique SA
Number of subjects: 270
Study 26026936 — intervention group
Group type: EXPERIMENTAL
Intervention: A1PI (α1 proteinase inhibitor) intravenously 60 mg/kg per week for 24 months
Number of subjects: 180
Study 26026936 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 180
Study 23329651 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 100
Study 21346517 — intervention group
Group type: EXPERIMENTAL
Intervention: music and art therapy and psychomotor activity
Number of subjects: 146
Study 21346517 — intervention group
Group type: COMPARATOR
Intervention: free activities in the day room
Number of subjects: 146
Study 19750958 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel dietary intervention
Number of subjects: 2175
Study 19750958 — intervention group
Group type: COMPARATOR
Intervention: Comparison ROs (Control)
Number of subjects: 2175
Study 17584552 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG timing method
Number of subjects: 175
Study 17584552 — intervention group
Group type: COMPARATOR
Intervention: Historical timing
Number of subjects: 175
Study 15171765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative skin remodeling with a 1540-nm Er:Glass laser
Number of subjects: 20
Study 11798458 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of consensus interferon (IFN-con1)
Number of subjects: 0
Study 11798458 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with consensus interferon (IFN-con1)
Number of subjects: 0
Study 11798458 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 levels
Number of subjects: 0
Study 11798458 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in IL-6 levels
Number of subjects: 0
Study 9716140 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA2 polymorphism
Number of subjects: 114
Study 9716140 — intervention group
Group type: COMPARATOR
Intervention: PLA polymorphisms
Number of subjects: 114
Study 9252796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen and sumatriptan
Number of subjects: 88
Study 9252796 — intervention group
Group type: COMPARATOR
Intervention: Placebo prophylaxis and sumatriptan
Number of subjects: 88
Study 9252796 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan alone
Number of subjects: 88
Study 1959364 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score (low score <= 9)
Number of subjects: 604
Study 1959364 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score (high score >= 25)
Number of subjects: 604
Study 1959364 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (normal score 14 to 15)
Number of subjects: 604
Study 1959364 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (low score 3)
Number of subjects: 604
Study 1959364 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Physiology Score model
Number of subjects: 604
Study 1959364 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score model
Number of subjects: 604
Study 1959364 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 604
Study 7077615 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-frequency (50 Hz) electric fields up to an intensity of 20 kV/m
Number of subjects: 10
Study 7077615 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 30971225 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/day, 4 × 40 mg capsules once daily)
Number of subjects: 100
Study 30971225 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (375 mg/day; 3 × 125 mg tablets thrice daily)
Number of subjects: 100
Study 30971225 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 100
Study 30971225 — intervention group
Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 100
Study 28849310 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields with temozolomide (n=210)
Number of subjects: 315
Study 28849310 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide alone (n=105)
Number of subjects: 315
Study 26074395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800mg/day
Number of subjects: 102
Study 26074395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 25149587 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow Controlled Expiration (FLEX)
Number of subjects: 24
Study 25149587 — intervention group
Group type: COMPARATOR
Intervention: Positive End Expiratory Pressure (PEEP=0, 3, 6 or 9 cmH2O)
Number of subjects: 24
Study 23077043 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI adaptation with repeated presentations of an object near the hand for different arm postures
Number of subjects: 0
Study 23077043 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived ownership of a prosthetic hand during an illusion
Number of subjects: 0
Study 23077043 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-hand space remapping in the premotor cortex
Number of subjects: 0
Study 23077043 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-hand space remapping in the posterior parietal cortex
Number of subjects: 0
Study 19387330 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg/min)
Number of subjects: 17
Study 19387330 — intervention group
Group type: COMPARATOR
Intervention: Saline + LPS (2 ng/kg)
Number of subjects: 17
Study 17250535 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.005 mg/mL
Number of subjects: 10
Study 17250535 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05 mg/mL
Number of subjects: 10
Study 17250535 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.5 mg/mL
Number of subjects: 10
Study 17250535 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 10
Study 15047241 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal lurtotecan at a dose of 2.4 mg/m(2) on Days 1 and 8 of a 21-day cycle
Number of subjects: 22
Study 12477021 — intervention group
Group type: EXPERIMENTAL
Intervention: Reichert AT550 non-contact tonometer
Number of subjects: 35
Study 12477021 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 35
Study 12477021 — intervention group
Group type: COMPARATOR
Intervention: Reichert Xpert Plus
Number of subjects: 35
Study 12477021 — intervention group
Group type: COMPARATOR
Intervention: Perkins tonometer
Number of subjects: 35
Study 9096985 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg b.i.d. BTS 67,582
Number of subjects: 18
Study 9096985 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg b.i.d. BTS 67,582
Number of subjects: 18
Study 9096985 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg q.d. BTS 67,582
Number of subjects: 18
Study 9096985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8256475 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture with electric needles (10 Hz, current titrated to individual threshold, 25 min each session) on acupuncture points Di4 [He Gu], Ma25 [Tian Shu], Le3 [Yuan], and B125 [Da Chang Yu]
Number of subjects: 8
Study 8256475 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture with electric needles
Number of subjects: 8
Study 3515923 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (Ansaid, Upjohn)
Number of subjects: 0
Study 3515923 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen plus etidocaine (long‐acting local anesthetic)
Number of subjects: 0
Study 3515923 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen alone or in combination with oxycodone
Number of subjects: 0
Study 3515923 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen/oxycodone and lidocaine
Number of subjects: 0
Study 31133457 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 0
Study 31133457 — intervention group
Group type: COMPARATOR
Intervention: Usual care (conventional subcutaneous insulin therapy)
Number of subjects: 0
Study 30387043 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 400-1200 mg/day
Number of subjects: 72
Study 26934620 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 229
Study 26934620 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 229
Study 24661523 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf pulmonary surfactant (50 mg/kg) within 6 hours after admission (Treatment group 1)
Number of subjects: 175
Study 24661523 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf pulmonary surfactant (70 mg/kg) within 6 hours after admission (Treatment group 2)
Number of subjects: 175
Study 24661523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PS within 6 hours after admission, PS (50 mg/kg) given later if no remission)
Number of subjects: 175
Study 22971501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 22971501 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 100
Study 20453654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fujinon Intelligent Color Enhancement (FICE) with magnification
Number of subjects: 144
Study 20453654 — intervention group
Group type: COMPARATOR
Intervention: Indigo carmine dye with magnification
Number of subjects: 144
Study 18819261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIFE) administration after ICD shock
Number of subjects: 25
Study 18819261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NIFE administration)
Number of subjects: 25
Study 16115099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydatid fluid (100 microg in 100 microl of PBS with FCA)
Number of subjects: 23
Study 16115099 — intervention group
Group type: EXPERIMENTAL
Intervention: Protoscolex proteins (100 microg in 100 microl of PBS with FCA)
Number of subjects: 23
Study 16115099 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body protein of E. granulosus (1 mg in 2 ml of PBS with FCA)
Number of subjects: 23
Study 16115099 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant in PBS (control for mice)
Number of subjects: 23
Study 16115099 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant in PBS (control for sheep)
Number of subjects: 23
Study 11954900 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulations (oral and transdermal) for steady pain management and fast-acting, immediate-release formulations for breakthrough pain management.
Number of subjects: 0
Study 11954900 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized opioid treatment based on drug absorption, metabolism, toxicity, and binding characteristics.
Number of subjects: 0
Study 10348790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 14C-labeled tacrolimus (0.01 mg/kg)
Number of subjects: 6
Study 10348790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 14C-labeled tacrolimus (0.05 mg/kg)
Number of subjects: 6
Study 8600865 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rH‐EPO)
Number of subjects: 0
Study 8600865 — intervention group
Group type: COMPARATOR
Intervention: EPO vehicle (Control)
Number of subjects: 0
Study 2064859 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine containing 1:80,000 adrenaline (Xylocaine)
Number of subjects: 20
Study 2064859 — intervention group
Group type: COMPARATOR
Intervention: 3% prilocaine with 0.03 IU/ml felypressin (Citanest)
Number of subjects: 20
Study 6844301 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment with advice for cholesterol lowering diet, smoking cessation, regular exercise, weight reduction, and drug control of hypertension for high-risk individuals; mass education for non-high-risk individuals.
Number of subjects: 63000
Study 6844301 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no individual treatment, only mass education for non-high-risk individuals.
Number of subjects: 63000
Study 31596444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, low-frequency oral psoralen-UV-A treatment
Number of subjects: 0
Study 31596444 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29698965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturia group (45 men)
Number of subjects: 138
Study 29698965 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 men)
Number of subjects: 138
Study 27267880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rotigotine (≤6 mg/24 h for early PD or ≤8 mg/24 h for advanced PD)
Number of subjects: 122
Study 27267880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rotigotine (≤8 mg/24 h for early PD or ≤16 mg/24 h for advanced PD)
Number of subjects: 122
Study 27267880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rotigotine
Number of subjects: 122
Study 27267880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rotigotine
Number of subjects: 122
Study 27267880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 24798657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg
Number of subjects: 11
Study 24798657 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 20 mg
Number of subjects: 11
Study 23057765 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 9
Study 23057765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk
Number of subjects: 9
Study 23057765 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted bovine whey protein
Number of subjects: 9
Study 23057765 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted bovine casein protein
Number of subjects: 9
Study 23057765 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (WWB)
Number of subjects: 9
Study 20588292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 932
Study 17380117 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB (TL‐01 lamps)
Number of subjects: 100
Study 17380117 — intervention group
Group type: COMPARATOR
Intervention: Selective broadband UVB (UV6 lamps)
Number of subjects: 100
Study 15627448 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy with oral antibiotics (Group A)
Number of subjects: 59
Study 15627448 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics without myringotomy (Group B)
Number of subjects: 59
Study 11978141 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% urea cream (Carmol 40)
Number of subjects: 25
Study 11978141 — intervention group
Group type: COMPARATOR
Intervention: 12% ammonium lactate lotion (Lac‐Hydrin 12%)
Number of subjects: 25
Study 9615361 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive idiopathic scoliosis
Number of subjects: 146
Study 9615361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprogressive idiopathic scoliosis
Number of subjects: 146